BRD4 and viral infectious disease: Because BRD4 has emerged as a protein target for the SARS-CoV-2 virus envelope protein E6, the TP-based inhibitors, and particularly the most potent compound SRX3212, could provide critical tools in determining the role of BRD4 in viral infections, including SARS-CoV types.